Krebs Biochemicals & Industries Ltd.
Snapshot View

130.60 -3.10 ▼-2.3%

30 July 2021, 04:00:00 P.M.
Volume: 8,013

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.krebsbiochem.com
Financial Indicators
Market Cap 281.58 Cr.
Earnings per share (EPS) -13.15 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share -14.10 Trailing Twelve Months Ending 2021-03
Price to Book Value -9.26 Calculated using Price: 130.60
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 2.16 Cr. 21,560,586 Shares
FaceValue 10
Company Profile

Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.

KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.

KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.

The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.

KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).

Product range of the company includes:

Bulk activities

Synthetic

  • Lavastatin
  • Simvastatin
  • I -Ephedrochiloride
  • l - Ephedrine Sulphate
  • l - Ephedrine Base (Liquid)
  • d - Pseudoephedrine Hydrochloride
  • d - Pseudoephedrine Sulphate
  • d - Pseudoephedrine Base
  • dl - Ephedrine Base
  • n - Methyl Ephedrine
  • d - Ephedrine Bitartarate
  • Vitamin C
  • Vitamin C (Coated)

Herbal

  • Calcium Sennosides - 20% & 60%
  • Garcinia Combogia Powdered Extract
  • Capsaicin - 50/100

Intermediates

  • Crude Lovastatin
  • Simvastatin Ammonium Salt

Products in pipeline

  • Pravastatin Sodium

Achievements/ recognition:

  • ISO 9002 in November 2001 
  • EDQM July 2003 
  • USFDA in November 2003 
  • ISO 9001 – 2000 in March 2004 
  • WHO GMP certification in November 2002 and renewed in March 2005

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.32%
1 Week
+13.57%
1 Month
+10.12%
3 Month
+3.45%
6 Month
+10.77%
1 Year
+56.03%
2 Year
+82.79%
5 Year
+69.72%
9 years 2012-03 2013-06 2014-09 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -55.86 -97.77 -75.26 -683.34 -296.70
Return on Capital Employed (%) -9.06 -14.60 -3.91 -4.33 -25.38 -27.13 -28.95 -35.41 -56.95
Return on Assets (%) -11.46 -10.72 -3.19 -6.44 -14.60 -13.46 -14.38 -14.92 -20.91

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-06 Rs. Cr. 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 23 8 4 18 13 1 -18 -14 -25
Non Curr. Liab. 66 57 23 60 74 89 101 102 116
Curr. Liab. 59 71 110 29 30 32 42 55 43
Minority Int.
Equity & Liab. 148 136 136 107 116 122 126 142 134
Non Curr. Assets 105 97 98 92 107 109 109 111 115
Curr. Assets 43 38 39 15 9 13 17 31 19
Misc. Exp. not W/O
Total Assets 148 136 136 107 116 122 126 142 134

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-06 Rs. Cr. 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 71 11 1 4 34 48 33
Other Income 3 6 0 0 1 0 0 0 0
Total Income 74 18 0 0 2 4 34 48 34
Total Expenditure -75 -25 -4 -5 -14 -12 -41 -58 -52
PBIDT -1 -7 -4 -5 -11 -8 -7 -9 -18
Interest -9 -1 0 -4 -1 -3 -5 -6 -6
Depreciation -10 -8 -2 -4 -4 -4 -4 -5
Taxation 2 1 0
Exceptional Items 3 0 0 -1 0
PAT -17 -15 -4 -8 -16 -16 -18 -20 -29

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-06 Rs. Cr. 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 7 -2 49 -45 -15 -11 -6 4 -36
Cash Fr. Inv. -1 6 0 -3 -4 -5 -3 -4 -9
Cash Fr. Finan. -6 -4 -49 54 13 16 9 17 28
Net Change 0 0 0 6 -6 0 0 17 -17
Cash & Cash Eqvt 0 0 0 6 0 0 0 17 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 64.66 64.66 64.66 67.35 70.05 70.05 70.05 70.05 72.74
Public 35.34 35.34 35.34 32.65 29.95 29.95 29.95 29.95 27.26
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 3.72 3.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 30 Jul 2021
Submission Of Quick Result For Quarter 30Th June 2021
We refer to the above mentioned subject we herewith submit to the Exchange the quick results for the quarter ended 30th June 2021 as approved by the Board of Directors at their meeting held on 30th July 2021.
Fri, 30 Jul 2021
Board Meeting Outcome for Out Come Of Board Meeting
we wish to inform the following outcome of the meeting of the Board of Directors held today i.e. 30th July 2021:

(a) The Un-Audited financial results for the quarter ended 30th June 2021 along with the Limited Review Report thereon (Enclosed herewith) have been adopted by the Board.
(b) The Board has taken note of Resignation of Mr. Manish Jain Director from the Board.
(c) The Board has taken note of end of tenure of Mr. Avinash Ravi as Managing Director and accordingly Change in designation of Mr. Avinash Ravi from Managing Director to Non-Executive Director.
(d) Appointment of Mr. Pabitra Bhattacharya as Additional Director and Managing Director of the Company subject to approval of members at the ensuing Annual General Meeting whose Brief profile is attached herewith.
Fri, 23 Jul 2021
Update on board meeting
KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2021 inter alia to consider and approve Update on board meeting
we herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Friday 30th July 2021 to transact inter alia the following:

1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter ended 30th June 2021.

2. Any other matter with the permission of the Chair.

Technical Scans View Details

Fri, 30 Jul 2021
Close Within 2 Year High Zone Close Within 2 Year High Zone
Either SRS Or ARS Going Below Zero Either SRS Or ARS Going Below Zero
ATR Increasing for 3 Days ATR Increasing for 3 Days
ATR Increasing for 5 Days ATR Increasing for 5 Days
Thu, 29 Jul 2021
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%